Potential Anti-epileptic Phytoconstituents: An Updated Review.

Kaur, J; Famta, P; Famta, M; Mehta, M; Satija, S; Sharma, N; Vyas, M; Khatik, GL; Chellappan, DK; Dua, K; Khurana, N

Potential Anti-epileptic Phytoconstituents: An Updated Review.

Kaur, J Famta, P Famta, M Mehta, M Satija, S Sharma, N Vyas, M Khatik, GL Chellappan, DK Dua, K

Khurana, N

Permalink

Publisher:: Elsevier BV
Publication Type:: Journal Article
Citation:: Journal of ethnopharmacology, 2020, pp. 113565
Issue Date:: 2020-11-06

Closed Access

	Filename	Description	Size
	1-s2.0-S037887412033453X-main.pdf	Accepted version	6.45 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Kaur, J
dc.contributor.author	Famta, P
dc.contributor.author	Famta, M
dc.contributor.author	Mehta, M
dc.contributor.author	Satija, S
dc.contributor.author	Sharma, N
dc.contributor.author	Vyas, M
dc.contributor.author	Khatik, GL
dc.contributor.author	Chellappan, DK
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Khurana, N
dc.date.accessioned	2020-11-24T04:34:22Z
dc.date.available	2020-11-05
dc.date.available	2020-11-24T04:34:22Z
dc.date.issued	2020-11-06
dc.identifier.citation	Journal of ethnopharmacology, 2020, pp. 113565
dc.identifier.issn	0378-8741
dc.identifier.issn	1872-7573
dc.identifier.uri	http://hdl.handle.net/10453/144306
dc.description.abstract	ETHNOPHARMACOLOGICAL RELEVANCE:Epilepsy is one of the most commonly occurring non-communicable neurological disorder that affects people of all age groups. Around 50 million people globally are epileptic, with 80% cases in developing countries due to lack of access to treatments determined by high cost and poor availability or it can be defined by the fraction of active epileptic patients who are not appropriately being treated. The availability of antiepileptic drugs and their adjuvant therapy in such countries is less than 50% and these are highly susceptible to drug interactions and severe adverse effects. As a result, the use of herbal medicine is increasingly becoming popular. AIM OF THE STUDY:To provide pharmacological information on the active constituents evaluated in the preclinical study to treat epilepsy with potential to be used as an alternative therapeutic option in future. It also provides affirmation for the development of novel antiepileptic drugs derived from medicinal plants. MATERIALS AND METHODS:Relevant information on the antiepileptic potential of phytoconstituents in the preclinical study (in-vitro, in-vivo) is provided based on their effect on screening parameters. Besides, relevant information on pharmacology of phytoconstituents, the traditional use of their medicinal plants related to epilepsy and status of phytoconstituents in the clinical study were derived from online databases, including PubMed, Clinicaltrial.gov, The Plant List (TPL, www.theplantlist.org), Science Direct. Articles identified using preset searching syntax and inclusion criteria are presented. RESULTS:More than 70% of the phytoconstituents reviewed in this paper justified the traditional use of their medicinal plant related to epilepsy by primarily acting on the GABAergic system. Amongst the phytoconstituents, only cannabidiol and tetrahydrocannabinol have been explored for clinical application in epilepsy. CONCLUSION:The preclinical and clinical data of the phytoconstituents to treat epilepsy and its associated comorbidities provides evidence for the discovery and development of novel antiepileptic drugs from medicinal plants. In terms of efficacy and safety, further randomized and controlled clinical studies are required to understand the complete pharmacodynamic and pharmacokinetic picture of phytoconstituents. Also, specific botanical source evaluation is needed.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Elsevier BV
dc.relation.ispartof	Journal of ethnopharmacology
dc.relation.isbasedon	10.1016/j.jep.2020.113565
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0607 Plant Biology, 1104 Complementary and Alternative Medicine, 1115 Pharmacology and Pharmaceutical Sciences
dc.subject.classification	Medicinal & Biomolecular Chemistry
dc.title	Potential Anti-epileptic Phytoconstituents: An Updated Review.
dc.type	Journal Article
utslib.location.activity	Ireland
utslib.for	0607 Plant Biology
utslib.for	1104 Complementary and Alternative Medicine
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
utslib.copyright.status	closed_access	*
dc.date.updated	2020-11-24T04:34:13Z
pubs.publication-status	Published

Abstract:

ETHNOPHARMACOLOGICAL RELEVANCE:Epilepsy is one of the most commonly occurring non-communicable neurological disorder that affects people of all age groups. Around 50 million people globally are epileptic, with 80% cases in developing countries due to lack of access to treatments determined by high cost and poor availability or it can be defined by the fraction of active epileptic patients who are not appropriately being treated. The availability of antiepileptic drugs and their adjuvant therapy in such countries is less than 50% and these are highly susceptible to drug interactions and severe adverse effects. As a result, the use of herbal medicine is increasingly becoming popular. AIM OF THE STUDY:To provide pharmacological information on the active constituents evaluated in the preclinical study to treat epilepsy with potential to be used as an alternative therapeutic option in future. It also provides affirmation for the development of novel antiepileptic drugs derived from medicinal plants. MATERIALS AND METHODS:Relevant information on the antiepileptic potential of phytoconstituents in the preclinical study (in-vitro, in-vivo) is provided based on their effect on screening parameters. Besides, relevant information on pharmacology of phytoconstituents, the traditional use of their medicinal plants related to epilepsy and status of phytoconstituents in the clinical study were derived from online databases, including PubMed, Clinicaltrial.gov, The Plant List (TPL, www.theplantlist.org), Science Direct. Articles identified using preset searching syntax and inclusion criteria are presented. RESULTS:More than 70% of the phytoconstituents reviewed in this paper justified the traditional use of their medicinal plant related to epilepsy by primarily acting on the GABAergic system. Amongst the phytoconstituents, only cannabidiol and tetrahydrocannabinol have been explored for clinical application in epilepsy. CONCLUSION:The preclinical and clinical data of the phytoconstituents to treat epilepsy and its associated comorbidities provides evidence for the discovery and development of novel antiepileptic drugs from medicinal plants. In terms of efficacy and safety, further randomized and controlled clinical studies are required to understand the complete pharmacodynamic and pharmacokinetic picture of phytoconstituents. Also, specific botanical source evaluation is needed.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/144306